文献速递胸部肿瘤

肺段与肺叶切除在病理侵袭性NSCLC中的比较:JCOG0802事后分析

Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L.
PubMed 文献 · J Thorac Oncol · 2026-05-11

该研究为JCOG0802/WJOG4607L随机III期试验的事后补充分析,纳入298例临床IA期(≤2cm)且病理有淋巴管、血管、胸膜侵犯或淋巴结转移的非小细胞肺癌患者。中位随访7.1年,肺段切除对比肺叶切除总生存呈更好趋势(HR 0.657,95%CI 0.401-1.077;p=0.0936),其他原因死亡累积发生率显著降低(HR 0.359),但局部区域复发累积发生率显著升高(HR 2.234)。

要点

  • 病理侵袭性NSCLC中肺段切除总生存呈优于肺叶切除趋势(HR 0.657,p=0.0936)。
  • 肺段切除其他原因死亡风险显著低于肺叶切除(HR 0.359,95%CI 0.143-0.900)。
  • 肺段切除局部区域复发风险显著高于肺叶切除(HR 2.234,95%CI 1.334-3.741)。

核心结论

  • 在具有病理侵袭性特征的小外周NSCLC中,肺段切除较肺叶切除显示更好的总生存趋势,但局部区域复发风险更高。

研究设计与样本

  • JCOG0802/WJOG4607L随机对照III期试验的事后补充分析。
  • 纳入临床IA期(≤2cm)且病理有淋巴管、血管、胸膜侵犯或淋巴结转移的NSCLC患者298例。
  • 肺叶切除组164例,肺段切除组134例;中位随访7.1年(四分位距5.9-8.4)。

主要发现

  • 总生存:肺段切除对比肺叶切除HR 0.657(95%CI 0.401-1.077;p=0.0936)。
  • 其他原因死亡累积发生率:肺段切除显著低于肺叶切除(HR 0.359,95%CI 0.143-0.900)。
  • 无复发生存和肺癌特异性死亡累积发生率两组无显著差异。
  • 局部区域复发累积发生率:肺段切除显著高于肺叶切除(HR 2.234,95%CI 1.334-3.741)。

关键数值与推荐

  • 病理侵袭性特征定义:淋巴管侵犯、血管侵犯、胸膜侵犯或淋巴结转移中至少一项。
  • 主要终点为总生存,次要终点包括无复发生存、局部区域复发累积发生率、肺癌特异性死亡及其他原因死亡。

临床怎么用

  • 对具有病理侵袭性特征的小外周NSCLC,肺段切除可作为考虑选项,但需警惕局部区域复发风险。
  • 术后应加强局部区域复发监测与随访。

局限性

  • 为事后补充分析,非预设主要分析,证据等级有限。
  • 仅纳入298例(27%)患者,样本量较小。
  • 总生存差异未达统计学显著性(p=0.0936)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Segmentectomy has become a standard treatment for small-sized peripheral NSCLC. However, its advantages compared with lobectomy in NSCLC harboring pathologically invasive features remain unclear. METHODS: We conducted a post hoc supplementary analysis of randomized controlled phase 3 trial JCOG0802/WJOG4607L in patients with clinical stage IA NSCLC (≤2 cm) harboring one or more of the following pathologically invasive features: lymphatic, vascular, or pleural invasion and lymph node metastasis. The primary outcome was overall survival (OS), and secondary outcomes were relapse-free survival, cumulative incidence of locoregional relapse, lung cancer-specific death, and death from other causes. RESULTS: Of the 1106 participants randomly assigned to the lobectomy or segmentectomy arm, 298 (27%) were included in this analysis: 164 patients were in the lobectomy arm and 134 in the segmentectomy arm. At a median follow-up of 7.1 (interquartile range: 5.9-8.4) years, segmentectomy demonstrated a trend toward better OS than lobectomy, with hazard ratio (HR) of 0.657 (95% confidence interval [CI]: 0.401-1.077; p = 0.0936). The cumulative incidence of death from other causes was significantly reduced in the segmentectomy arm compared with the lobectomy arm (HR = 0.359 [95% CI: 0.143-0.900]). Relapse-free survival and cumulative incidence of lung cancer-specific death were not significantly different between the two arms, whereas the cumulative incidence of locoregional relapse was significantly higher in the segmentectomy than in the lobectomy arm (HR = 2.234 [95% CI: 1.334-3.741]). CONCLUSIONS: Segmentectomy demonstrated better OS compared with lobectomy even for NSCLC harboring pathologically invasive features. However, the risk of locoregional relapse after segmentectomy should be considered.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Katsumata S, Kamigaichi A, Akamine T, et al. Segmentectomy Versus Lobectomy in NSCLC With Pathologically Invasive Features: A Post Hoc Supplementary Analysis of Multicenter, Phase 3 Trial JCOG0802/WJOG4607L. J Thorac Oncol. 2026. PMID: 42119729. doi:10.1016/j.jtho.2026.103916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。